SLC22A1 and chronic myelogenous leukemia, BCR-ABL1 positive: Monitoring of the gene expression of imatinib transporters OCT1 or ABCB1 was not found applicable as markers of resistance to imatinib because their expressions significantly vary among the cell types that are present in samples of bone marrow or peripheral blood of CML patients [7, 8].